Bayer Leverages AWS Data Science for Pharma R&D
Bayer is building a cloud-based data science ecosystem using AWS SageMaker to enhance its pharmaceutical research and development processes.
Global health and nutrition company Bayer has developed a cloud-based data science ecosystem utilizing Amazon Web Services (AWS) to accelerate its pharmaceutical research and development.
The new ecosystem, powered by AWS's Amazon SageMaker service, unifies data ingestion, storage, analytics, and machine learning workflows. The aim is to empower Bayer's research teams with enhanced capabilities to analyze complex scientific data and leverage artificial intelligence (AI) and machine learning (ML) for drug discovery.
Bayer states that this data-centric approach enables more agile experimentation and scalable insight generation. The ecosystem is designed to democratize access to analytics tools and foster cross-regional collaboration, by flexibly integrating various data formats.
Data is a critical asset for driving innovation in the pharmaceutical industry. Bayer's investment in AWS-based data science is part of the company's mission to improve global health and food security, supporting its 'Health for All, Hunger for None' commitment.